Neonatal alloimmune thrombocytopenia (NAIT) is a condition that occurs when a mother’s immune system produces antibodies against her baby's platelets, leading to low platelet counts in the newborn.

A 2-week-old child who presented with petechiae was found to have a very low platelet count and was diagnosed with fetal and neonatal alloimmune thrombocytopenia (FNAIT). This case report was ...

ic.ac.uk Neonatal thrombocytopenia is a common clinical problem. Thrombocytopenia presenting in the first 72 hours of life is usually secondary to placental insufficiency and caused by reduced ...

Neonatal alloimmune neutropenia (NAN) is a condition where a newborn's neutrophils, a type of white blood cell crucial for fighting infections, are destroyed by antibodies produced in response to ...

and in March this year for foetal neonatal alloimmune thrombocytopenia treatment. J&J Innovative Medicine Rheumatology and Immunology Disease Area leader and vice-president Terence Rooney said ...

Following Johnson & Johnson’s (J&J) recent US Food and Drug Administration (FDA) fast track designation of nipocalimab for the reduction of foetal and neonatal alloimmune thrombocytopenia (FNAIT ...

[2] Platelet destruction in the neonate can be from an immune response to antibodies in the neonatal circulation. In the following sections, autoimmune and alloimmune thrombocytopenia will be ...

which could improve practices for families affected by fetal and neonatal alloimmune thrombocytopenia (FNAIT), according to a study published in JAMA Network Open. This nonrandomized clinical trial, ...

In a poster titled "Prophylactic Administration of HPA-1a–Specific Antibody RLYB212 Safely Prevents Fetal/Neonatal Alloimmune Thrombocytopenia Due to HPA-1a Incompatibility in Pregnant Mice ...

JMP Securities analyst Jonathan Wolleben reiterated a Buy rating on Rallybio (RLYB – Research Report) today and set a price target of ...

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today ...